HSA-based multi-target combination therapy: regulating drugs' release from HSA and overcoming single drug resistance in a breast cancer model
Multi-drug delivery systems, which may be promising solution to overcome obstacles, have limited the clinical success of multi-drug combination therapies to treat cancer. To this end, we used three different anticancer agents, Cu(BpT)Br, NAMI-A, and doxorubicin (DOX), to build human serum albumin (H...
Saved in:
Main Authors: | Yi Gou (Author), Zhenlei Zhang (Author), Dongyang Li (Author), Lei Zhao (Author), Meiling Cai (Author), Zhewen Sun (Author), Yongping Li (Author), Yao Zhang (Author), Hamid Khan (Author), Hongbing Sun (Author), Tao Wang (Author), Hong Liang (Author), Feng Yang (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2018-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison of Losartan and Furosemide Interaction with HSA and Their Influence on HSA Antioxidant Potential
by: Wojciech Rogóż, et al.
Published: (2022) -
Circular RNAs hsa-circ0000175 and hsa-circ0044235 in plasma are novel biomarkers for new-onset rheumatoid arthritis
by: Yujie Gao, et al.
Published: (2021) -
Salivary microRNAs (hsa-miR-200a, hsa-miR-125a and hsa- miR-93) in relation to age, gender and histopathological parameters.
by: Shaimaa H Mudhir, et al.
Published: (2014) -
Hsa_circ_0043532 contributes to PCOS through upregulation of CYP19A1 by acting as a ceRNA for hsa-miR-1270
by: Huimin Zhang, et al.
Published: (2024) -
The validity of salivary microRNAs (hsa-miR-200a, hsa-miR-125a and hsa- miR-93) as oral squamous cell carcinoma biomarker
by: Shaimaa H Mudhir, et al.
Published: (2014)